-continued

```
225                 230                 235                 240

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
                245                 250                 255

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
            260                 265                 270

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
        275                 280                 285

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
    290                 295                 300

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
305                 310                 315                 320

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
                325                 330                 335

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
            340                 345                 350

Pro Gly Thr Gly Xaa Gly Xaa Xaa Gly Xaa Xaa Gly Xaa Gly Thr Phe
        355                 360                 365

Gly Thr Gly Gly Ala Ser Ala Gln Ala Ser Leu Ala Ser Lys Asp Lys
    370                 375                 380

Thr Pro Lys Ser Lys Ser Lys Lys Gly Gly Ser Thr Gln Leu Lys Ser
385                 390                 395                 400

Arg Val Lys Asn Ile
                405
```

1. A compound comprising a fusion protein, comprising an antibody or fragment thereof that transmigrates the blood brain barrier (BBB) a polypeptide that binds β-amyloid.

2. The compound of claim **1** further comprising a Fc fragment.

3. The compound of claim **1** or **2**, wherein the polypeptide that binds β-amyloid comprises a sequence

(SEQ ID NO: 31)
$X_1TFX_2TX_3X_4ASAQASLASKDKTPKSKSKKX_5X_6STQLX_7SX_8VX_9NI$

wherein X_1 = G or A, X_2 = G or V, X_3 = G or A, X_4 = G or A, X_5 = G or V, X_6 = G or V, X_7 = G or V, X_8 = G or A, X_9 = G or A.

3. The compound of claim **2**, wherein the polypeptide that binds β-amyloid comprises a sequence selected from the group consisting of:

(SEQ ID NO: 27)
SGKTEYMAFPKPFESSSSIGAEKPRNKKLPEEEVESSRTPWLYEQEGEVE KPFIKTGFSVSVEKSTSSNRKNQLDTNGRRRQFDEESLESFSSMPDPVDP TTVTKTFKTRKASAQASLASKDKTPKSKSKKRNSTQLKSRVKNITHARRI LQQSNRNACNEAPETGSDFSMFEA;

(SEQ ID NO: 28)
FSSMPDPVDPTTVTKTFKTRKASAQASLASKDKTPKSKSK;

-continued

(SEQ ID NO: 29)
KDKTPKSKSKKRNSTQLKSRVKNITHARRILQQSNRNACN;

(SEQ ID NO: 30)
KTFKTRKASAQASLASKDKTPKSKSKKRNSTQLKSRVKNI;

(SEQ ID NO: 32)
KTFKTRKASAQASLASKDKTPKSKSKKRGSTQLKSRVKNI;

(SEQ ID NO: 33)
KTFKTRKASAQASLASKDKTPKSKSKKGGSTQLKSRVKNI;

(SEQ ID NO: 34)
KTFKTRGASAQASLASKDKTPKSKSKKRGSTQLKSRVKNI;

(SEQ ID NO: 35)
KTFKTGGASAQASLASKDKTPKSKSKKRGSTQLKSRVKNI;

(SEQ ID NO: 36)
GTFGTGGASAQASLASKDKTPKSKSKKGGSTQLKSRVKNI;

(SEQ ID NO: 37)
KTFKTRKASAQASLASKDKTPKSKSKKGGSTVKNI;

(SEQ ID NO: 38)
KTFKTRKASAQASLASKDKTPKSKSKKRG;

and

a sequence substantially identical to any of the above sequences.

4. The compound of any one of claims **1** to **3**, wherein the antibody or fragment thereof comprises a sequence selected from the group consisting of:

an antibody or fragment thereof comprising a complementarity determining region (CDR) 1 sequence of GFKITHYTMG (SEQ ID NO:1), a CDR2 sequence of